Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin for Anxiety, Depression and Sleep in Blepharospasm
NCT04939909Phase 1Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jul 2021
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of botulinum toxin type A in benign essential blepharospasm (BEB), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Change from baseline blepharospasm evaluation at 3 months. Status: unknown.
02
Drugs
botulinum toxin type A
03
Conditions
benign essential blepharospasm (BEB)
Beyond the preview
Go deeper on NCT04939909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04939909.